Your session is about to expire
Dovato vs Truvada
Introduction
For individuals living with Human Immunodeficiency Virus (HIV), specific antiretroviral drugs that limit the ability of the virus to replicate within the body can help in managing symptoms and slowing disease progression. Dovato and Truvada are two such medications commonly prescribed for HIV treatment or prevention. They each target different stages of the HIV life cycle, but both have significant effects in managing this chronic condition. Dovato is a combination medication containing dolutegravir, an integrase inhibitor, and lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI). It works by blocking certain enzymes necessary for viral replication. On the other hand, Truvada combines emtricitabine and tenofovir disoproxil fumarate - two NRTIs which interfere with one of these essential enzymes: reverse transcriptase.
Dovato vs Truvada Side By Side
| Attribute | Dovato | Truvada |
|---|---|---|
| Brand Name | Dovato | Truvada |
| Contraindications | Cannot be taken with certain drugs like dofetilide due to potential for serious drug interactions. Not suitable for patients with worsening symptoms of immune reconstitution syndrome. | Cannot be taken with certain drugs like dofetilide due to potential for serious drug interactions. Not suitable for patients with worsening symptoms of immune reconstitution syndrome. |
| Cost | $2,500 to $3,000 per month | $1,600-$2,000 per month |
| Generic Name | Dolutegravir/Lamivudine | Emtricitabine/Tenofovir Disoproxil Fumarate |
| Most Serious Side Effect | Signs of an allergic reaction, severe liver problems, unexplained muscle pain, symptoms related to immune reconstitution inflammatory syndrome. | Lactic acidosis, kidney problems, liver problems, changes in body fat distribution. |
| Severe Drug Interactions | Dofetilide and other drugs that may interact with dolutegravir or lamivudine. | Dofetilide and other drugs that may interact with emtricitabine or tenofovir disoproxil fumarate. |
| Typical Dose | One tablet (50 mg dolutegravir and 300 mg lamivudine) taken orally once a day | One tablet (200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) per day |
What is Dovato?
Dolutegravir/Lamivudine (the generic names for Dovato) is a newer, two-drug combination used to treat HIV-1 infection. It was first approved by the FDA in 2019 and represents a significant advancement over older antiretroviral therapies, such as Truvada. Dovato works by blocking the enzyme that HIV needs to multiply while simultaneously preventing the virus from integrating into human DNA, effectively trapping it and reducing its ability to cause harm. This medication is prescribed for adults with no prior antiretroviral treatment history or for those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. One major advantage of Dovato over other treatments like Truvada is that it uses fewer drugs but maintains high efficacy, which may result in fewer side effects and drug interactions.
What conditions is Dovato approved to treat?
Dovato is approved for the management of specific medical conditions:
- HIV-1 infection in adults with no previous antiretroviral treatment history
- HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato.
How does Dovato help with these illnesses?
Dovato helps manage HIV by blocking the action of certain enzymes that are needed for the virus to multiply in your body. It does this by containing two active substances, dolutegravir and lamivudine which inhibit key processes used by the HIV virus to replicate. Dolutegravir is an integrase inhibitor, blocking a viral enzyme called integrase which prevents HIV from integrating its genetic material into human cells, while lamivudine is a reverse transcriptase inhibitor that blocks another enzyme (reverse transcriptase) used by HIV to replicate itself. By inhibiting these enzymes, Dovato can limit the replication of the virus and help patients manage their condition more effectively.
On the other hand, Truvada also treats and prevents HIV but it includes two different active ingredients - emtricitabine and tenofovir disoproxil fumarate - both of which are also reverse transcriptase inhibitors. The choice between these medications often depends on individual patient factors such as potential side effects, drug interactions and overall health status.
What is Truvada?
Truvada, a brand name for the combination of emtricitabine and tenofovir disoproxil fumarate, is a nucleoside reverse transcriptase inhibitor (NRTI) used to treat HIV. Truvada works by inhibiting an enzyme called reverse transcriptase that HIV uses to replicate itself. This medication was first approved by the FDA in 2004 and has since been widely used as part of antiretroviral therapy (ART). Unlike Dovato which contains two active ingredients, dolutegravir and lamivudine; Truvada does not contain any integrase inhibitors like dolutegravir but instead combines two NRTIs. The side effect profiles also vary with Truvada less likely to cause insomnia or headaches compared to Dovato, but it may lead to other side effects such as kidney problems or bone loss. Both medications are crucial components in managing HIV infection; however, treatment choice would depend on individual patient factors including existing medical conditions and potential drug interactions.
What conditions is Truvada approved to treat?
Truvada has been approved by the FDA for use in treating and preventing:
- HIV-1 infection when used in combination with other antiretroviral agents, particularly for those who are at high risk of getting infected.
- Chronic hepatitis B virus (HBV) infections. It's important to note that while Truvada can help manage these conditions, it is not a cure.
How does Truvada help with these illnesses?
Truvada is a cornerstone in the treatment and prevention of HIV. It works by blocking reverse transcriptase, an enzyme that plays a critical role in the viral replication process. This antiretroviral therapy combines two medications - emtricitabine and tenofovir disoproxil fumarate, which effectively prevent the virus from multiplying and spreading throughout the body.
While Dovato also contains two active ingredients (dolutegravir and lamivudine) to suppress viral replication, Truvada has been used extensively for pre-exposure prophylaxis (PrEP), where it's taken by individuals who are at high risk but not yet infected with HIV to prevent contracting the virus. In this preventative context, Truvada has proven highly effective. Its antiviral action may be augmented when combined with other antiretroviral drugs in patients already diagnosed with HIV.
How effective are both Dovato and Truvada?
Both Dovato and Truvada have made significant strides in the treatment of HIV, with their approvals by the FDA coming over a decade apart. As they have different active ingredients - Dovato containing dolutegravir and lamivudine, while Truvada combines emtricitabine and tenofovir disoproxil fumarate – they may be chosen under differing medical scenarios. A 2019 clinical trial directly studied the effectiveness of Dovato compared to regimens containing Truvada for treating patients new to antiretroviral therapy; both treatments displayed comparable efficacy in viral suppression as well as similar safety profiles. The study found no substantial differences in key metrics measuring success in HIV management between patients receiving regimens involving Dovato or those including Truvada.
A 2020 review pointed out that Dovato offers an effective two-drug regimen alternative starting from first-time treatment initiation, demonstrating its efficiency at achieving viral suppression within initial weeks of therapy. Its side effects profile shows fewer potential kidney and bone density issues than some other medications used for HIV, making it generally well-tolerated even among patient populations with existing kidney conditions or osteoporosis risks.
Truvada has been extensively studied since its approval in 2004 not only as part of highly active antiretroviral therapy (HAART) but also as pre-exposure prophylaxis (PrEP) for preventing HIV infection among high-risk populations. It is considered a primary option due to extensive data on its efficacy alongside various third agents. Although there are concerns about long-term use causing renal impairment or reduction in bone mineral density, these side effects need to be weighed against the proven benefits offered by this medication.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Dovato typically prescribed?
The standard dosage for Dovato, used in the treatment of HIV infection, is one tablet (containing 50 mg dolutegravir and 300 mg lamivudine) taken orally once a day. Similarly, Truvada (200mg emtricitabine/300mg tenofovir disoproxil fumarate), also used to treat HIV infection or for pre-exposure prophylaxis (PrEP), should be taken once daily with or without food. It's important to remember that these medications must always be used as part of a comprehensive strategy including other preventative measures and not as standalone treatments. The dosages are generally the same across adults and adolescents over the age of 12 who weigh at least 35 kg; however, individual responses should be monitored by healthcare providers regularly.
At what dose is Truvada typically prescribed?
Truvada's treatment is usually initiated at a dosage of one tablet (200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) per day. The dose remains consistent, without the need for increment. It can be taken with or without food and should be swallowed whole to ensure you receive the full dosage. Regular kidney function tests are recommended due to potential risk of renal impairment associated with Truvada use. There may also be a need for dose adjustment in patients with renal dysfunction. If after few weeks symptoms persist or worsen, it is advisable to consult your healthcare provider.
What are the most common side effects for Dovato?
Common side effects of Dovato, an antiretroviral drug used to treat HIV/AIDS, can include:
- Headache
- Diarrhea
- Nausea
- Fatigue and general weakness
- Insomnia or sleep disorders
- Abdominal pain or discomfort in the digestive tract
Meanwhile, Truvada users may experience some similar symptoms as well as others such as:
- Decrease in bone mineral density leading to bone pain or fractures
- Rash and other skin problems
- Changes in body fat distribution (lipodystrophy) -Lactic acidosis (excessive lactic acid build-up in the blood) which can cause nausea, vomiting, unusual muscle pain and difficulty breathing.
Remember that not everyone experiences all these side effects. The severity also differs between individuals. If you're considering either Dovato or Truvada for treatment consult with your healthcare provider who will guide you towards the most appropriate option based on your overall health status and lifestyle.
Are there any potential serious side effects for Dovato?
While both Dovato and Truvada are effective medications for managing HIV, they may occasionally cause severe side effects. For Dovato, these may include:
- Signs of an allergic reaction such as hives or itching, difficulty breathing or swallowing; swelling in your face or throat.
- Changes in body fat distribution - an increase in fat on the upper back and neck ("buffalo hump"), around the chest, and stomach area; loss of fat from arms, legs, and face.
- Severe liver problems: yellowing of skin or eyes (jaundice), dark-colored urine, light-colored bowel movements.
- Unexplained muscle pain, tenderness, weakness especially if you also have fever.
- Symptoms related to immune reconstitution inflammatory syndrome: a condition that sometimes occurs when the immune system starts to recover after treatment with an HIV medicine.
For Truvada some serious side effects can be:
- Lactic acidosis symptoms: unusual muscle pain or discomfort; feeling cold all over your body; trouble breathing; unexplained nausea & vomiting
- Kidney issues: urinating less often than usual or not at all; increased thirstiness
- Bone problems like bone pain Any occurrences should lead to immediate consultation with your healthcare provider.
What are the most common side effects for Truvada?
Truvada, a common medication used in the treatment and prevention of HIV, can have several potential side effects. These can include:
- Nausea, vomiting, sometimes accompanied by stomach pain
- Loss of appetite which may lead to weight loss over time
- Difficulty sleeping (insomnia)
- Headaches and dizziness
- Muscle or joint pain
- Mild skin rash Additionally, some people might experience more serious side effects such as lactic acidosis (a buildup of an acid in the blood), liver problems or changes in body fat distribution. Regular medical check-up is crucial when using Truvada to monitor these possible adverse reactions.
Are there any potential serious side effects for Truvada?
While Truvada is widely employed in the management of HIV, it can occasionally lead to serious side effects. These may include:
- Symptoms indicative of an allergic reaction such as hives, itching, swelling on your face or throat, difficulty breathing and fever
- Changes in body fat distribution - gaining weight around your waist while losing weight from legs, arms and face
- Signs of new infection like flu symptoms; sores in mouth or on skin; night sweats
- Kidney problems with signs like changes in urination pattern or lower back pain
- Liver problems which may present as nausea, upper stomach pain spreading to your back accompanied by tiredness and loss of appetite
- Lactic acidosis symptoms: unusual muscle discomfort, vomiting or nausea leading to severe weakness.
If you experience any aforementioned symptoms while taking Truvada consult with a healthcare professional immediately.
Contraindications for Dovato and Truvada?
Both Dovato and Truvada, along with most other antiretroviral medications, may worsen symptoms of immune reconstitution syndrome in some people. If you notice your condition worsening or an increase in side effects such as fever, inflammation or flare-ups of previous infections after starting these medications, seek immediate medical attention.
Neither Dovato nor Truvada can be taken if you are taking or have been taking certain drugs like dofetilide (a medication for irregular heartbeat) due to the potential for serious drug interactions. Always inform your physician which medications you are currently on; some medicines will require a certain period to clear from the system to prevent dangerous interactions with Dovato and Truvada.
It's also important to note that while both Dovato and Truvada are used in HIV treatment regimens, they aren't interchangeable - they contain different active ingredients and work in slightly different ways. Always consult with a healthcare provider before making changes to your treatment plan.
How much do Dovato and Truvada cost?
For the brand name versions of these drugs:
- The price of 30 tablets of Dovato (dolutegravir/lamivudine) averages around $2,500 to $3,000 per month depending on where you purchase it from. This works out to about $83-$100/day.
- The price for a monthly supply (30 tablets) of Truvada (emtricitabine/tenofovir disoproxil fumarate), without insurance, can range from approximately $1,600-$2,000 or even more in some locations—working out to roughly $53-$67/day.
Consequently, if cost is a significant factor for you and both are suitable options according to your doctor's advice—you may find Truvada less expensive on a daily use basis compared with Dovato. However, please remember that cost should not be the sole determinant in choosing which medication is right for you; efficacy and safety profiles also matter.
Unfortunately at this time there are no generic versions available for either Dovato or Truvada in most Western countries due their respective patents still being active. Therefore we cannot provide cost comparisons as we do with Prozac and Wellbutrin above. Always consult your healthcare provider when deciding between medications.
Popularity of Dovato and Truvada
Dolutegravir/lamivudine, in generic form as well as brand names such as Dovato, was estimated to have been prescribed to about 2.3 million people in the US in 2020. Dolutegravir/lamivudine accounted for just over 15% of antiretroviral prescriptions in the US. However, it appears to be one of the most commonly used "two-drug" regimens (as opposed to traditional three-drug regimens) for HIV treatment and has been generally increasing in prevalence since its approval by FDA in 2019.
Emtricitabine/tenofovir disoproxil fumarate, including brand versions such as Truvada, was prescribed to approximately 4 million people in the USA during 2020 alone. In the US, emtricitabine/tenofovir accounts for nearly a quarter of all antiretroviral prescriptions and is widely accepted due its effectiveness at not only treating but also preventing HIV infection - known medically as pre-exposure prophylaxis or PrEP - when taken daily. The prevalence of emtricitabine/tenofovir has remained stable over recent years.
Conclusion
Both Dovato (dolutegravir/lamivudine) and Truvada (emtricitabine/tenofovir disoproxil fumarate) have established records of usage in patients with HIV, backed by numerous clinical studies showing they are more effective than placebo treatments. In some instances, these drugs may be used together under the careful supervision of a physician; however, interactions between them can occur.
Dovato and Truvada function differently: Dovato is an integrase inhibitor combined with a nucleoside reverse transcriptase inhibitor (NRTI), primarily working to block the virus from integrating into human DNA. On the other hand, Truvada contains two NRTIs which work synergistically to inhibit viral replication.
Truvada is often prescribed as part of first-line antiretroviral therapy or for pre-exposure prophylaxis (PrEP) against HIV infection whereas Dovato is typically used as a complete regimen for the treatment of HIV-1 infection in adults with no previous antiretroviral treatment history.
Both medicines are available in generic form offering significant cost savings especially for those paying out-of-pocket. Both Dovato and Truvada may require time before their effects become noticeable due to adjustments within your body's system.
Side effect profiles are similar between both drugs but vary based on individual response. Common side effects include headache, nausea and diarrhea while serious side effects such as kidney problems or decreased bone density tend to occur less frequently but still warrant immediate medical attention if experienced. Like all medications treating chronic conditions like HIV/AIDS, it's crucial that patients closely monitor their health status when starting treatment.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Muñoz de Benito, R. M., & Arribas López, J. R. (2006, August). Tenofovir disoproxil fumarate–emtricitabine coformulation for once-daily dual NRTI backbone. Expert Review of Anti-infective Therapy. Informa UK Limited.http://doi.org/10.1586/14787210.4.4.523
- Gazzard, B. G. (2006, March 24). Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients. Expert Opinion on Pharmacotherapy. Informa UK Limited.http://doi.org/10.1517/14656566.7.6.793
- Kearney, B. P., Yale, K., Shah, J., Zhong, L., & Flaherty, J. F. (2006). Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment. Clinical Pharmacokinetics. Springer Science and Business Media LLC.http://doi.org/10.2165/00003088-200645110-00005
- DiBonaventura, M. daCosta ., Gupta, S., Cho, M., & Mrus, J. (2012, January 31). The association of HIV/AIDS treatment side effects with health status, work productivity, and resource use. AIDS Care. Informa UK Limited.http://doi.org/10.1080/09540121.2011.630363
- Walmsley, S., Baumgarten, A., Berenguer, J., Felizarta, F., Florence, E., Khuong-Josses, M.-A., … Pappa, K. (2015, December 15). Brief Report. JAIDS Journal of Acquired Immune Deficiency Syndromes. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/qai.0000000000000790
- Keeshin, S. W., & Feinberg, J. (2014, October 27). Evaluation of dolutegravir safety for the treatment of HIV-1. Expert Opinion on Drug Safety. Informa UK Limited.http://doi.org/10.1517/14740338.2015.973845